A Phase 1 Study to Evaluate the Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 07 Mar 2019
Price : $35 *
At a glance
- Drugs Pevonedistat (Primary) ; Carboplatin; Docetaxel; Fluconazole; Itraconazole; Paclitaxel
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Takeda Oncology
- 07 Mar 2019 Results published in the British Journal of Clinical Pharmacology
- 13 Dec 2017 Status changed from active, no longer recruiting to completed.
- 09 Mar 2017 Status changed to active, no longer recruiting.